Michael Yee News
-
Gilead Sciences Inc. rose to its highest price ever on optimism over potential sales for the company’s experimental hepatitis C medications.
-
Chili peppers and migraines have traits in common, a fact scientists are exploiting to develop drugs capable of preventing the debilitating headache’s painful symptoms before they attack.
-
Biogen Idec Inc. won European Union backing for Tecfidera, one of the first therapies for multiple sclerosis available in an easy-to-take pill that analysts say may generate $3.25 billion in annual sales.
-
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, rose to a record price after the drugmaker won U.S. approval for its first pill for multiple sclerosis, Tecfidera.
-
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, rose to a record price after the drugmaker won U.S. approval for its first pill for multiple sclerosis, Tecfidera.
-
Biogen Idec Inc., the fourth- largest U.S. biotechnology company by market value, won a U.S. patent that may guard its experimental multiple sclerosis pill from generic competition for eight more years than anticipated.
-
Genzyme Corp. , a takeover target of Sanofi-Aventis SA , expects to complete sales of its diagnostics and pharmaceutical-ingredients units by the end of the year.
-
Elan Corp.’s impending cash influx will give the drug developer leeway to buy something it lacks: a product.
-
Robert W. Duggan, the Church of Scientology’s biggest donor and the chief executive officer of Pharmacyclics Inc., which makes an experimental treatment for chronic lymphocytic leukemia, has become a billionaire after the company’s shares tripled in a year.
-
Myriad Genetics Inc. Chief Executive Officer Pete Meldrum says his lab test to pinpoint tumors with a specific genetic mutation could have helped Sanofi-Aventis SA succeed if it had been used in a study of a drug that failed in breast cancer.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page